Literature DB >> 12660008

Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor.

Kosuke Kashiwabara1, Syu-ichi Koshi, Kotaro Itonaga, Osamu Nakahara, Makoto Tanaka, Masakazu Toyonaga.   

Abstract

GOALS OF THE STUDY: To evaluate the outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. PATIENTS AND METHODS: This study enrolled 198 asymptomatic patients with lung cancer found by lung cancer mass screening during the 9-year period. Five-year survival rates in patients who did not consult a doctor or who stopped consulting a doctor in spite of abnormal shadows detected on last mass screening chest roentgenograms (n=45, delayed consultation group) and in patients who subsequently consulted a doctor when abnormal shadows were detected (n=153, control group) were evaluated by the method of Kaplan and Meier and clinical variables were examined as possible predictors of survival time by the Cox proportional-hazards model.
RESULTS: There was a significant difference between the 5-year survival rates in the delayed consultation group and in the control group (21 vs. 51%, log rank: P=0.0003, Wilcoxon: P=0.0009). The risk of death increased 115.0% for the 1-year delay in consultation (hazard ratio: 2.150, 95% CI: 1.203-3.842, P=0.0097). With regard to the reason why they did not consult a doctor, many of them answered that they did not have any respiratory symptoms.
CONCLUSION: The 1-year delay in consultation had a great significance in that these patients did not receive any treatment for lung cancer for 1 year, and the 1-year delay in treatment itself affected the outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12660008     DOI: 10.1016/s0169-5002(02)00505-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  The relationship of cancer characteristics and patient outcome with time to lung cancer diagnosis after an abnormal screening CT.

Authors:  Sushilkumar K Sonavane; Paul Pinsky; Jubal Watts; David S Gierada; Reginald Munden; Satinder P Singh; Hrudaya Nath
Journal:  Eur Radiol       Date:  2017-06-14       Impact factor: 5.315

2.  Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait?

Authors:  Amelia W Maiga; Stephen A Deppen; Rhonda Pinkerman; Carol Callaway-Lane; Pierre P Massion; Robert S Dittus; Eric S Lambright; Jonathan C Nesbitt; David Baker; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2017-10-21       Impact factor: 4.330

3.  Time to treatment and survival in veterans with lung cancer eligible for curative intent therapy.

Authors:  Duc Ha; Andrew L Ries; Philippe Montgrain; Florin Vaida; Svetlana Sheinkman; Mark M Fuster
Journal:  Respir Med       Date:  2018-07-17       Impact factor: 3.415

4.  Guideline-concordant timely lung cancer care and prognosis among elderly patients in the United States: A population-based study.

Authors:  Pramit Nadpara; S Suresh Madhavan; Cindy Tworek
Journal:  Cancer Epidemiol       Date:  2015-06-29       Impact factor: 2.984

5.  Level of Awareness of Various Aspects of Lung Cancer Among College Teachers in India: Impact of Cancer Awareness Programmes in Prevention and Early Detection.

Authors:  Abhishek Shankar; Shubham Roy; Abhidha Malik; G K Rath; P K Julka; Vineet Kumar Kamal; Keshav Barnwal; Sneha Upadhyaya; Rajan Singh; Vivek Srivastava
Journal:  J Cancer Educ       Date:  2016-12       Impact factor: 2.037

6.  Time to treatment in patients with stage III non-small cell lung cancer.

Authors:  Li Wang; Candace R Correa; James A Hayman; Lujun Zhao; Kemp Cease; Dean Brenner; Doug Arenberg; Jeffery Curtis; Gregory P Kalemkerian; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

7.  Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?

Authors:  Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

8.  Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases.

Authors:  Matthew Freedman; Esther H Chang; Qi Zhou; Kathleen F Pirollo
Journal:  Acad Radiol       Date:  2009-05       Impact factor: 3.173

9.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Authors:  Chyke A Doubeni; Nicole B Gabler; Cosette M Wheeler; Anne Marie McCarthy; Philip E Castle; Ethan A Halm; Mitchell D Schnall; Celette S Skinner; Anna N A Tosteson; Donald L Weaver; Anil Vachani; Shivan J Mehta; Katharine A Rendle; Stacey A Fedewa; Douglas A Corley; Katrina Armstrong
Journal:  CA Cancer J Clin       Date:  2018-03-30       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.